Your browser doesn't support javascript.
loading
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.
Delaby, Constance; Teunissen, Charlotte E; Blennow, Kaj; Alcolea, Daniel; Arisi, Ivan; Amar, Elodie Bouaziz; Beaume, Anne; Bedel, Aurélie; Bellomo, Giovanni; Bigot-Corbel, Edith; Bjerke, Maria; Blanc-Quintin, Marie-Céline; Boada, Mercè; Bousiges, Olivier; Chapman, Miles D; DeMarco, Mari L; D'Onofrio, Mara; Dumurgier, Julien; Dufour-Rainfray, Diane; Engelborghs, Sebastiaan; Esselmann, Hermann; Fogli, Anne; Gabelle, Audrey; Galloni, Elisabetta; Gondolf, Clémentine; Grandhomme, Frédérique; Grau-Rivera, Oriol; Hart, Melanie; Ikeuchi, Takeshi; Jeromin, Andreas; Kasuga, Kensaku; Keshavan, Ashvini; Khalil, Michael; Körtvelyessy, Peter; Kulczynska-Przybik, Agnieszka; Laplanche, Jean-Louis; Lewczuk, Piotr; Li, Qiao-Xin; Lleó, Alberto; Malaplate, Catherine; Marquié, Marta; Masters, Colin L; Mroczko, Barbara; Nogueira, Léonor; Orellana, Adelina; Otto, Markus; Oudart, Jean-Baptiste; Paquet, Claire; Paoletti, Federico Paolini; Parnetti, Lucilla.
Afiliação
  • Delaby C; LBPC-PPC, Univ Montpellier, CHU Montpellier, INSERM, Montpellier, France.
  • Teunissen CE; Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Blennow K; Neurochemistry Lab, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Alcolea D; Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Arisi I; Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Amar EB; European Brain Research Institute (EBRI) "Rita Levi-Montalcini", Roma, Italy.
  • Beaume A; Université de Paris, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, Paris, France.
  • Bedel A; CHU Poitiers, Poitiers, France.
  • Bellomo G; CHU Bordeaux, Bordeaux, France.
  • Bigot-Corbel E; Lab of Clinical Neurochemistry, Section of Neurology, Dept. of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • Bjerke M; Laboratoire de Biochimie, Hôpital G & R Laënnec, CHU de Nantes, Nantes, France.
  • Blanc-Quintin MC; Vrije Universiteit Brussel, Center for Neurosciences and Department of Clinical Biology, Clinical Neurochemistry Laboratory, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Boada M; Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Bousiges O; APHP Centre-Université de Paris, Cochin Hospital, Paris, France.
  • Chapman MD; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades and Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
  • DeMarco ML; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • D'Onofrio M; Laboratoire de Biochimie et Biologie Moléculaire, et CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Dumurgier J; Department of Neuroimmunology, National Hospital for Neurology and Neurosurgery, UCL Queen Square, London, UK.
  • Dufour-Rainfray D; Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada & Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada.
  • Engelborghs S; European Brain Research Institute (EBRI) "Rita Levi-Montalcini", Roma, Italy.
  • Esselmann H; Université de Paris, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, Paris, France.
  • Fogli A; CHU Tours, UMR 1253- iBrain, Tours, France.
  • Gabelle A; Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Galloni E; Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Center for Neurosciences and Department of Neurology, Brussels, Belgium.
  • Gondolf C; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG, Goettingen, Germany.
  • Grandhomme F; CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Grau-Rivera O; LBPC-PPC, Univ Montpellier, CHU Montpellier, INSERM, Montpellier, France.
  • Hart M; Dipartimento di Neuroscienze Divisione di Neurologia, Vicenza, Italy.
  • Ikeuchi T; CHU Cote de Nacre Caen, Caen, France.
  • Jeromin A; CHU Cote de Nacre Caen, Caen, France.
  • Kasuga K; Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Keshavan A; Servei de Neurologia, Hospital del Mar, Unitat de deteriorament cognitiu i transtorns del moviment, Barcelona, Spain.
  • Khalil M; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Körtvelyessy P; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
  • Kulczynska-Przybik A; Department of Neuroimmunology, National Hospital for Neurology and Neurosurgery, UCL Queen Square, London, UK.
  • Laplanche JL; Dept. of Molecular Genetics, Center for Bioresources, Brain Research Institute, Niigata University, Niigata, Japan.
  • Lewczuk P; Cohen Veterans Bioscience, Cambridge, Massachusetts, USA.
  • Li QX; Dept. of Molecular Genetics, Center for Bioresources, Brain Research Institute, Niigata University, Niigata, Japan.
  • Lleó A; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
  • Malaplate C; Medical University of Graz, Graz, Austria.
  • Marquié M; Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, German Center for Neurodegenerative Diseases, Magdeburg, Germany and Charité-Universitäts medizin Berlin, Berlin, Germany.
  • Masters CL; Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.
  • Mroczko B; Université de Paris, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, Paris, France.
  • Nogueira L; Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.
  • Orellana A; Lab for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Otto M; Florey Institute and The University of Melbourne, Melbourne, Victoria, Australia.
  • Oudart JB; Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Paquet C; CHRU de Nancy, Laboratoire de Biochimie, Biologie Moléculaire et Nutrition/ Université de Lorraine, Nancy, France.
  • Paoletti FP; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades and Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
  • Parnetti L; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Alzheimers Dement ; 18(10): 1868-1879, 2022 10.
Article em En | MEDLINE | ID: mdl-34936194
ABSTRACT

INTRODUCTION:

The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests.

METHODS:

We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients.

RESULTS:

The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis.

DISCUSSION:

This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França